

C9581

Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon

ClinicalTrials.gov Identifier: NCT00002968

Study Background

Trial Description

Randomized phase III trial to compare the effectiveness of surgery with or without monoclonal antibody therapy in treating patients who have stage II colon cancer. Monoclonal antibodies such as edrecolomab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether surgery to remove colon cancer is more effective with or without monoclonal antibody therapy.

Arms:

Arm I (edrecolomab): (Experimental): Patients receive adjuvant edrecolomab IV over 2 hours on day 1. Treatment repeats every 28 days for 5 courses. Patients must begin therapy no earlier than 7 days and no later than 42 days postsurgical resection. Patients also undergo observation at 3 and 6 months postrandomization.

Arm II (no treatment): (No Intervention): Patients undergo observation at 3 and 6 months postrandomization.

Objectives:

PRIMARY OBJECTIVES:

- I. To determine whether adjuvant treatment with MoAb 17-1A will improve the probability of overall and disease-free survival, and increase disease-free intervals in patients who have undergone resection of a Stage II colon cancer.
- II. To determine whether alterations in the expression of cell cycle related genes (thymidylate synthase, p53, and the cyclin-dependent kinase inhibitors p21 and p27) predict the risk of survival and recurrence in this patient population.
- III. To determine whether alterations in markers of metastatic potential-expression of DCC and measures of tumor angiogenesis (microvascular density and vascular endothelial growth factor expression)-predict the risk of survival and recurrence in this patient population.

IV. To determine whether a marker of cellular differentiation-sucrase isomaltase-predicts the risk of survival and recurrence in this patient population.

V. To determine whether DNA ploidy and cell proliferation are prognostic of tumor recurrence and overall survival in Stage II colon cancer.

VI. To determine whether interactions among these tumor markers identify subsets of patients with significantly altered outcome.

VII. To determine whether pathologic features including tumor grade; tumor mitotic (proliferation) index; tumor border configuration; host lymphoid response to tumor; and lymphatic vessel, venous vessel and perineural invasion predict outcome in this patient population.

Publication Information:

Analysis Type: Primary

PubMed ID: 21747085

Citation: [J Clin Oncol.](#) 2011 Aug 10;29(23):3146-52. doi: 10.1200/JCO.2010.32.5357.
Epub 2011 Jul 11.

Associated Datasets:

NCT00002968-D1-Dataset.csv (adverse_event_exp)

NCT00002968-D2-Dataset.csv (new_primary_exp)

NCT00002968-D3-Dataset.csv (off_trt_exp)

NCT00002968-D4-Dataset.csv (onstudy_exp)

NCT00002968-D5-Dataset.csv (outcome_other_baseline_data_exp)

NCT00002968-D6-Dataset.csv (adverse_event_control)

NCT00002968-D7-Dataset.csv (new_primary_control)

NCT00002968-D8-Dataset.csv (off_trt_control)

NCT00002968-D9-Dataset.csv (onstudy_control)

NCT00002968-D10-Dataset.csv (outcome_other_baseline_data_control)

Dataset Information:

Dataset Name: NCT00002968-D7-Dataset.csv (new_primary_control)

Description: Dataset NCT00002968-D7-Dataset.csv (new_primary_control) is one of 10 datasets associated with PubMed ID 21747085. This dataset contains information for the presence of new primary disease sites on the control arm.

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Blank values indicate data not applicable or missing, except where otherwise noted.

NCT00002968-D7-Dataset (new_primary_control) Data Dictionary:

Variable Name	Values	Variable Label	Comments
patid		De-identified Patient ID	
new_malig_type1	Missing=unknown	New Malignancy Type 1	
new_malig_site1		New Malignancy Site 1	Available data is cutoff at 20 characters.
new_malig_hist1		New Malignancy Histology 1	Available data is cutoff at 20 characters.
new_malig_type2		New Malignancy Type 2	
new_malig_site2		New Malignancy Site 2	Available data is cutoff at 20 characters.
new_malig_hist2		New Malignancy Histology 2	Available data is cutoff at 20 characters.